Primary drug resistance among HIV-1 patients in Hubei Province in 2020-2022
10.3969/j.issn.1006-2483.2024.01.011
- VernacularTitle:2020—2022年湖北省HIV-1感染者治疗前耐药状况分析
- Author:
Meng GUO
1
;
Fanghua MEI
1
;
Cong LIU
1
;
Kangping ZHOU
1
;
Junqiang XYU
1
;
Kun CAI
1
Author Information
1. Hubei Center for Disease Control and Prevention , Wuhan , Hubei 430079 , China
- Publication Type:Journal Article
- Keywords:
HIV-1 infected patients;
Primary drug resistance;
Sub-type;
Mutation site
- From:
Journal of Public Health and Preventive Medicine
2024;35(1):49-52
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the prevalence of primary drug resistance among HIV-1 patients in Hubei Province from 2020 to 2022, and to provide corresponding basis and data support for HIV antiviral therapy (ART) in Hubei Province. Methods During 2020-2022, plasma samples of HIV-1 infected patients before ART were collected., Patients’ demographic data and baseline laboratory test data were also collected. HIV-1 pol region was amplified by in-house method for sub-type typing and drug-resistant mutation site analysis. Results The pol gene sequence was successfully amplified in 242 of 285 cases, with a success rate of 84.9%. CRF07_BC was the predominant HIV-1 sub-type, accounting for 47.11% (114/242), followed by CRF01_AE, accounting for 25.21% (61/242), sub-type B, accounting for 14.16% (35/242), and CRF55_01B, accounting for 4.13% (10/242). The primary resistance rate was 6.20% (15/242). The mutation site of nucleoside reverse transcriptase inhibitors (NRTIs) was mainly M184V, and the mutation sites of non-nucleoside reverse transcriptase inhibitors (NNRTIs) were mainly E138A/G/EG and V179E. These different mutation sites led to different degrees of drug resistance to 12 drugs. The incidence of drug resistance mutation of CRF55_01B sub-type was significantly higher than that of other sub-types. Conclusion The primary drug resistance rate of HIV-1 infected patients is at a slightly high level in Hubei Province, and close monitoring of primary drug resistance and mutation sites should be strengthened before ART, especially for CRF55_01B sub-type.
